Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

We aimed to distinguish between fibrolamellar hepatocellular carcinoma and scirrhous hepatocellular carcinoma histopathologically.

Methods and results

In this review, fibrolamellar hepatocellular carcinoma and scirrhous hepatocellular carcinoma two specific and rare variants of hepatocellular carcinoma, which are difficult to diagnose histopathologically are discussed.

Conclusion

The clinical, radiological, gross, histopathological, immunohistochemical, and molecular features of these two tumors, which are defined by the World Health Organization (WHO), are mentioned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–30.

    CAS  PubMed  Google Scholar 

  2. Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am. 2017;46(2):365–91.

    Google Scholar 

  3. Sooklim K, Sriplung H, Piratvisuth T. Histologic subtypes of hepatocellular carcinoma in the southern Thai population. Asian Pac J Cancer Prev. 2003;4(4):302–6.

    PubMed  Google Scholar 

  4. Limaiem F, Bouraoui S, Sboui M, Bouslama S, Lahmar A, Mzabi S. Fibrolamellar carcinoma versus scirrhous hepatocellular carcinoma: diagnostic usefulness of CD68. Acta Gastroenterol Belg. 2015;78(4):393–8.

    PubMed  Google Scholar 

  5. Kim YJ, Rhee H, Yoo JE, Alves VAF, Kim GJ, Kim HM, et al. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. Histopathology. 2017;71(2):217–26.

    PubMed  Google Scholar 

  6. Polavarapu AD, Ahmed M, Samaha G, Weerasinghe KG, Deeb L, Sokoloff A. Spontaneous rupture of fibrolamellar variant hepatocellular carcinoma. Gastroenterol Res. 2019;12(3):166–70.

    Google Scholar 

  7. Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14(1):151–6.

    PubMed  PubMed Central  Google Scholar 

  8. Imai T, Yokoi H, Noguchi T, Kawarada Y, Mizumoto R. Fibrolamellar carcinoma of the liver--a case report. Gastroenterol Jpn. 1991;26(3):382–9.

    CAS  PubMed  Google Scholar 

  9. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–9.

    CAS  PubMed  Google Scholar 

  10. Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo). 2012;2012:743790.

    Google Scholar 

  11. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J. 2013;1:351–7.

    PubMed  PubMed Central  Google Scholar 

  12. Shafizadeh N, Kakar S. Hepatocellular carcinoma: histologic subtypes. Surg Pathol Clin. 2013;6(2):367–84.

    PubMed  Google Scholar 

  13. Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18:1417–23.

    PubMed  Google Scholar 

  14. Buckley AF, Burgart L, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37(4):410–4.

    CAS  PubMed  Google Scholar 

  15. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803.

    PubMed  Google Scholar 

  16. Ganehan D, Szklaruk J, Kaseb A, Katlan A, Elsayen KM. Fibrolamellar-HCC. Abdom Radiol (NY). 2018;43(12):3340–8.

    Google Scholar 

  17. McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999;19(2):453–71.

    CAS  PubMed  Google Scholar 

  18. Ariizumi S, Takasaki K, Otsubo T, Yamamoto M, Nakano M. Four immunohistochemically different primary liver cancers in one patient. J Gastroenterol. 2002;37(9):750–4.

    PubMed  Google Scholar 

  19. Lee JH, Choi MS, Gwak GY, Lee JH, Koh KC, Paik SW, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci. 2012;57(6):1698–707.

    PubMed  Google Scholar 

  20. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol. 2005;19(1):39–62.

    PubMed  Google Scholar 

  21. Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Fukuda K, et al. Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies. World J Gastroenterol. 2009;15(18):2296–9.

    PubMed  PubMed Central  Google Scholar 

  22. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;2:1470–7.

    Google Scholar 

  23. Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2009;69:123–30.

    PubMed  Google Scholar 

  24. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21(9):1470–7.

    PubMed  Google Scholar 

  25. Lalazar G, Simon SM. Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms. Semin Liver Dis. 2018;38(1):51–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Goodman ZD, Terracciano ML, Wee A. Tumours and tumour-like lesions of the liver. In: MacSweens’s Pathology of the Liver. 6th ed: Churchill Livingstone Elsevier; 2012. p. 761–828.

  27. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19(7):784–94.

    CAS  PubMed  Google Scholar 

  28. Lefkowitch JH, Muschel R, Price JB, Marboe C, Braunhut S. Copper and copper-binding protein in fibrolamellar liver cell carcinoma. Cancer. 1983;51(1):97–100.

    CAS  PubMed  Google Scholar 

  29. Soyer P, Bluemke DA, Vissuzaine C, Beers BV, Barge J, Levesque M. CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR Am J Roentgenol. 1994;162(5):1119–22.

    CAS  PubMed  Google Scholar 

  30. Fujii T, Zen Y, Harada K, Niwa H, Masuda S, Kaizaki Y, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma--human and cell culture study. Hum Pathol. 2008;39(8):1185–96.

    CAS  PubMed  Google Scholar 

  31. Fujii T, Zen Y, Nakanuma Y. Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. Pathol Int. 2007;57(7):443–8.

    PubMed  Google Scholar 

  32. Agni RM. Diagnostic histopathology of hepatocellular carcinoma: a case-based review. Semin Diagn Pathol. 2017;34(2):126–37.

    PubMed  Google Scholar 

  33. Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013;243.

  34. Jabbour TE, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists’ review. World Journal of Surgical Oncology. 2016;14:151–78.

    Google Scholar 

  35. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27.

    PubMed  Google Scholar 

  36. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667–76.

    CAS  PubMed  Google Scholar 

  37. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45:42–52.

    CAS  PubMed  Google Scholar 

  38. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67:727–38.

    CAS  PubMed  Google Scholar 

  40. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343:1010–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Graham RP, Jin L, Knutson DL, Kloft-Nelson SM, Greipp PT, Waldburger N, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28:822–9.

    CAS  PubMed  Google Scholar 

  42. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, Chen CC, et al. DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017;114(50):13076–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Griffith OL, Griffith M, Krysiak K, Magrini V, Ramu A, Skidmore ZL, et al. A genomic case study of mixed fibrolamellar hepatocellular carcinoma. Ann Oncol. 2016;27(6):1148–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial–mesenchymal transition. Hepatology. 2012;55:1776–86.

    CAS  PubMed  Google Scholar 

  45. Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim H, et al. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One. 2014;9(8):e105094.

    PubMed  PubMed Central  Google Scholar 

  46. Matsuura S, Aishima S, Taguchi K, Asayama Y, Terashi T, Honda H, et al. ‘Scirrhous’ type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47(4):382–90.

    CAS  PubMed  Google Scholar 

  47. Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, Zhang X, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod Pathol. 2019;32(10):1486–94.

    CAS  PubMed  Google Scholar 

  48. Ross HM, Daniel HDJ, Vivekanandan P, Kannangai R, Yeh MM, Wu TT, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2011;24(3):390–5.

    CAS  PubMed  Google Scholar 

  49. Riggle KM, Turnham R, Scott JD, Yeung RS, Riehle KJ. Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma. Pediatr Blood Cancer. 2016;63(7):1163–7.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Institute, Pathology Department, Inonu University, School of Medicine, Malatya, Turkey

    Emine Turkmen Samdanci, Ayse Nur Akatli & Nese Karadag Soylu

Authors
  1. Emine Turkmen Samdanci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayse Nur Akatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nese Karadag Soylu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emine Turkmen Samdanci.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samdanci, E.T., Akatli, A.N. & Soylu, N.K. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma. J Gastrointest Canc 51, 1187–1192 (2020). https://doi.org/10.1007/s12029-020-00500-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00500-1

Keywords

Search

Navigation